202002-66-2

Usage

Uses

Used in Pharmaceutical Industry:
2-(Piperidin-4-yl)acetonitrile is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs and enhance the properties of existing ones.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(Piperidin-4-yl)acetonitrile is utilized as an intermediate in the production of agrochemicals, playing a crucial role in the formulation of pesticides and other agricultural chemicals to improve crop protection and yield.
Used in Organic Chemistry:
2-(Piperidin-4-yl)acetonitrile is employed as a building block in organic chemistry for its capacity to form the basis of more complex organic compounds, contributing to the advancement of organic synthesis and the creation of novel chemical entities.
Used in Chemical Reactions:
As a reagent, 2-(Piperidin-4-yl)acetonitrile is used in various chemical reactions to facilitate specific transformations, providing a means to achieve desired outcomes in synthetic pathways.
Used in Material Science:
2-(Piperidin-4-yl)acetonitrile is considered as a precursor for the development of new materials, indicating its potential in contributing to the innovation of materials with unique properties for diverse applications.

Upstream product

• 256411-39-9 tert-butyl 4-(cyanomethyl)piperidine-1-carboxylate 
• 383865-57-4 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 197569-11-2 4-(cyanomethylidene)piperidine-1-carboxylic acid tert-butyl ester 
• 51052-78-9 4-piperidinylacetic acid 
• 184044-10-8 4-piperidineacetamide 

Downstream Products

• 153567-02-3 4-(2-aminoethyl)-1-(cyclohexylmethyl)piperidine 
• 86945-25-7 4-(2-aminoethyl)-1-(phenylmethyl)piperidine 

Relevant academic research and scientific papers

CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE UNCHARGED BISOXIME ANTIDOTES FOR ORGANOPHOSPHATE POISONING AND METHODS FOR MAKING AND USING THEM

In alternative embodiments, provided are uncharged bis-oxime antidotes that cross the blood-brain barrier (BBB) to catalyze the hydrolysis of organophosphate (OP)-inhibited human acetylcholinesterase (hAChE) in the central nerve system (CNS). In alternative embodiments, provided are pumps, devices, subcutaneous infusion devices, continuous subcutaneous infusion devices, infusion pens, needles, reservoirs, ampoules, a vial, a syringe, a cartridge, a disposable pen or jet injector, a prefilled pen or a syringe or a cartridge, a cartridge or a disposable pen or jet injector, a two chambered or multi-chambered pump, a syringe, a cartridge or a pen or a jet injector, comprising a compound as provided herein.

Structure-activity relationship study of tryptophan-based butyrylcholinesterase inhibitors

A series of tryptophan-based selective nanomolar butyrylcholinesterase (BChE) inhibitors was designed and synthesized. Compounds were optimized in terms of potency, selectivity, and synthetic accessibility. The crystal structure of the inhibitor 18 in complex with BChE revealed the molecular basis for its low nanomolar inhibition (IC50 = 2.8 nM). The favourable in vitro results enabled a first-in-animal in vivo efficacy and safety trial, which demonstrated a positive impact on fear-motivated and spatial long-term memory retrieval without any concomitant adverse motor effects. Altogether, this research culminated in a handful of new lead compounds with promising potential for symptomatic treatment of patients with Alzheimer's disease.

Corresponding amine nitrile and method of manufacturing thereof

The invention relates to a manufacturing method of nitrile. Compared with the prior art, the manufacturing method has the characteristics of significantly reduced using amount of an ammonia source, low environmental pressure, low energy consumption, low production cost, high purity and yield of a nitrile product and the like, and nitrile with a more complex structure can be obtained. The invention also relates to a method for manufacturing corresponding amine from nitrile.

COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

The present invention relates to compounds of formula I: in which n, Y, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention fur

5-HT7 RECEPTOR ANTAGONISTS

The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine: where A is C(H)= or -N= and R1-7 are as defined herein.

A distal methyl substituent attenuates mitochondrial protein synthesis inhibition in oxazolidinone antibacterials

Oxazolidinone analogs bearing substituted piperidine or azetidine C-rings are described. Analogs with a methyl group at the 3-position of the azetidine ring or the 4-position of the piperidine ring exhibited reduced mitochondrial protein synthesis inhibition while retaining good antibacterial potency.

Benzothiazole derivatives with activity as adenosine receptor ligands

The present invention relates to substituted benzothiazole derivitives and to their pharmaceutically acceptable salts useful for the treatment of diseases related to the adenosine receptor.